Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model

Nuclear Medicine and Biology

Volumn 23, Issue 8, 1996, Pages 935-940

  Louw, W K A ^a,e   Dormehl, I C ^b   Van Rensburg, A J ^b   Hugo, N ^b   Alberts, A S ^b   Forsyth, O E ^a   Beverley, G ^c   Sweetlove, M A ^d   Marais, J ^d   Lotter M G ^d   Van Aswegen, A ^d  

^a NECSA   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c H A Grove Research Centre   (South Africa)

^d UNIVERSITY OF THE FREE STATE   (South Africa)

^e AEC P3000   (South Africa)

Author keywords

baboon model; EDTMP; holmium 166; pharmacokinetics; samarium 153

Indexed keywords

ETHYLENEDIAMINE TETRAKIS(METHYLENEPHOSPHONIC ACID); HOLMIUM 166 EDTMP; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153 EDTMP; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BABOON; BONE; BONE METASTASIS; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOKINETICS; RADIOISOTOPE THERAPY;

ABSORPTION; ANIMALS; BODY FLUID COMPARTMENTS; BONE AND BONES; EVALUATION STUDIES; HALF-LIFE; HOLMIUM; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAPIO; RADIOISOTOPES; RADIOPHARMACEUTICALS; SAMARIUM; TISSUE DISTRIBUTION;

EID: 0030293890     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(96)00117-5     Document Type: Article

References (29)

1. 166Ho-EDTMP. Blood 80, 1608-1613.
2. 2. Arnold, J. S. (1979) Kinetic analysis of bone imaging agents. In: Principles of Radiopharmacology, Vol. III (Edited by Colombetti L. G.), pp. 205-223. CRC Press, Boca Raton, FL.
3. 3. Bayouth J. E., Macey D. J., Kasi L. P. and Fosella F. V. (1994) Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J. Nucl. Med. 35, 63-69.
4. 4. Eary J. F., Collins C., Stabin M., Vernon C., Petersdorf S., Baker M., Hartnett S., Ferency S., Addison S. J., Appelbaum F. and Gordon E. E. (1993) Samarium-153-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med. 34, 1031-1036.
5. 5. Farhanghi M., Holmes R. A., Volkerr W. A., Logan K. W. and Singh A. (1992) Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med. 33, 1451-1458.
6. 6. Fridman E. P. and Popova V. N. (1988) Species of the genus Papio (Cercopithecidae) as subjects of biomedical research: I. Biological basis of experiments on baboons. J. Med. Primatol. 17, 291-307.
7. 7. Fridman E. P. and Popova V. N. (1988) Species of the genus Papio (Cercopithecidae, Primates) as subjects of biomedical research: II. Quantitative characteristics of contemporary use of baboon species in medical and biological investigations. J. Med. Primatol. 17, 309-318.
8. 8. Goeckeler W. F., Edwards B., Volkert W. A., Holmes R. A., Simon J. and Wilson D. (1987) Skeletal localization of samarium-153-chelates: Potential therapeutic bone agents. J. Nucl. Med. 28, 495-504.
9. 9. Hoefnagel C. A. (1991) Radionuclide therapy revisited. Eur. J. Nucl. Med. 18, 408-431.
10. 153Sm]EDTMP: A potential therapy for bone cancer pain. Semin. Nucl. Med. 22, 41-45.
11. 11. Hosain F. and Spencer R. P. (1992) Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin. Nucl. Med. 22, 11-16.
12. 12. Humm J. L. (1986) Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. Nucl. Med. 27, 1490-1497.
13. 13. International Commission on Radiological Protection (1990) 1990 recommendations of the ICRP. Ann. ICRP 21, 1-201.
14. 14. Lattimer J. C., Corwin L. A., Stapleton J., Volkert W. A., Ehrhardt G. J., Ketring A. R., Hewett J. E., Simon J. and Goeckeler W. F. (1990) Clinical and clinopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J. Nucl. Med. 31, 586-593.
15. 15. Lattimer J. C., Corwin L. A., Stapleton J., Volkert W. A., Ehrhardt G. J., Ketring A. R., Anderson S. K., Simon J. and Goeckeler W. F. (1990) Clinical and clinicopathologic response to canine bone tumor patients to treatment with samarium-153-EDTMP. J. Nucl. Med. 31, 1316-1325.
16. 16. Loevinger R, Budlinger T. F. and Watson E. E. (1991) MIRD Primer for Absorbed Dose Calculations, pp. 1-21. Society of Nuclear Medicine, New York.
17. 17. Logan K. W., Volkert W. A. and Holmes R. A. (1987) Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J. Nucl. Med. 28, 505-509.
18. 18. Louw W. K. A., van Rensburg E. J., Izatt H. and Engelbrecht R. I. (1991) Nucleoid sedimentation analysis of DNA superstructure, γ-radiation-induced damage and repair in human and chacma baboon (Papio ursinus) peripheral lymphocytes. Int. J. Radiat. Biol. 59, 951-962.
19. 19. Moedritzer K. and Irani R. R. (1966) The direct synthesis of α-aminomethyl-phosphonic acids: Mannich-type reactions with orthophosphorous acid. J. Org. Chem. 31, 1603-1607.
20. 20. Parks N. J., Kawakami T. G., Avila M. J., White R., Cain G. R., Raaka S. D., Hornoff W., Fisher P., Moore P., Seibert J. A., Garlich J., Simon J. and Champlin R. (1993) Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP). Blood 82, 318-325.
21. 21. Rao D. V. and Howell R. W. (1993) Time-dose-fractionation in radioimmunotherapy: Implications for selecting radionuclides. J. Nucl. Med. 34, 1801-1810.
22. 22. Robinson R. G. (1990) Systemic radioisotopic therapy of primary and metastatic bone cancer. J. Nucl. Med. 31, 1326-1327.
23. 23. Spencer R. P. (1986) Applied principles of radiopharmaceutical use in therapy. Nucl. Med. Biol. 13, 461-463.
24. 24. Spencer R. P. (1987) Short-lived radionuclides in therapy. Nucl. Med. Biol. 14, 537-538.
25. 25. Turner J. H., Martindale A. A., Sorby P., Hetherington E. L., Fleay R. F., Huffman R. F. and Claringbold P. G. (1989) Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur. J. Nucl. Med. 15, 784-795.
26. 26. Volkert W. A., Goeckeler W. F., Ehrhardt G. J. and Ketring A. R. (1991) Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med. 32, 174-185.
27. 27. Wagener J. M. and Jarvis N. V. (1995) Complexation of trivalent lanthanides by ethylenediaminetetramethylphosphonate (EDTMP). S. Afr. J. Chem. 48, 85-89.
28. 28. Wessels B. W. and Rogus R. D. (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med. Phys. 11, 638-645.
29. 29. Wheldon T. E. (1993) Radionuclide therapy of cancer: Particle range and therapeutic effectiveness. Nucl. Med. Commun. 14, 408-410.